Join CancerNetwork&#x27;s Survivorship Tweet Chat

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Leticia Nogueira, PhD, MPH

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

CHMP Recommends Acalabrutinib Combo Approval in Untreated MCL

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma

Results from the phase 3 ECHO trial showed PFS and OS improvements with acalabrutinib in the first-line treatment of MCL compared with standard of care.

Related Content

$Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.$

Roman Fabbricatore

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

Leticia Nogueira, PhD, MPH

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

CHMP Recommends Acalabrutinib Combo Approval in Untreated MCL

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.